• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Meta-Analysis: Are Adverse Pregnancy Outcomes Associated with Hodgkin Lymphoma?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Houlihan et al. (BJOG, 2022) synthesized the published literature on the relationship between Hodgkin lymphoma (HL) and maternal and perinatal outcomes

METHODS:

  • Systematic review and meta-analysis
  • Study inclusion criteria
    • Reported original data
    • Compared a previous or current diagnosis of HL to no previous or current HL and reported pregnancy or neonatal outcomes
  • Study design
    • Where data permitted, meta-analyses of odds ratios (OR) and proportions were performed
    • Certainty of evidence was determined using GRADE criteria
  • Primary outcomes
    • Congenital malformations
    • Preterm birth
    • Miscarriage

RESULTS:

  • 33 studies
  • Certainty of evidence ranged from very low to low

HL before or during pregnancy vs controls was not associated with increased risk for

  • Congenital malformations
    • HL before pregnancy: aOR 1.7 (95% CI, 0.9 to 3.1)
    • HL during pregnancy: aOR 1.84 (95% CI, 0.81 to 4.15)
  • Preterm birth
    • HL before pregnancy: aOR 0.99 (95% CI, 0.65 to 1.51)
    • HL during pregnancy: aOR 6.74 (95% CI, 0.52 to 88.03)
  • Miscarriage
    • HL before pregnancy: aOR 0.78 (95% CI, 0.55 to 1.10)
    • HL during pregnancy: aOR 0.38 (95% CI, 0.05 to 2.72)

HL diagnosed during pregnancy was associated with increased risk for

  • Blood transfusion: aOR 1.38 (95% CI, 1.05 to 1.82)
  • Venous thromboembolism: aOR 7.93 (95% CI, 2.97 to 21.22)
  • Anemia
    • HL during pregnancy: 69% (95% CI, 57 to 80)
    • Control: 4% (95% CI, 4 to 5)

CONCLUSION:

  • Compared to the general pregnant population, individuals with HL diagnosed before or during pregnancy, do not appear to be at increased risk for congenital malformations, preterm birth, or miscarriage
  • Women with HL during pregnancy may experience more venous thromboembolism, anemia, and require more blood transfusions
  • The authors state

Future primary research should be based on large cohorts of pregnant women with a current or previous diagnosis of HL and should stratify the outcome data by timing and treatment received, parity, race, and ethnicity

Data should also be reported separately for elective and emergency CS and planned and spontaneous PTB to further inform management decisions during pregnancy

Learn More – Primary Sources:

Maternal and perinatal outcomes following a diagnosis of Hodgkin lymphoma during or prior to pregnancy: a systematic review

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Cohort Study: When Noninvasive Prenatal Screening Reveals a Potential Maternal Cancer
What are Reproductive Outcomes Among Cancer Survivors?
Radioactive Iodine Treatment for Thyroid Cancer: How Long to Wait to Become Pregnant?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site